Research & Development News Channel

Clinical trial completion rates decline during COVID-19 pandemic

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected clinical researchers' ability to finish trials. Study completion rates dropped worldwide between 13% and 23%, depending on the type of research sponsor and geographic location, between April and October 2020.

Study identifies possible COVID-19 drugs - including several that are FDA-approved

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that are already approved by the Food and Drug Administration (FDA) for treating other diseases.

COVID-19 convalescent plasma with greater antibody levels is safe and shows promise

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels of antibodies, according to a new publication by scientists at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network.

Prioritizing who gets vaccinated for COVID-19 saves lives

Waiting for your turn can be frustrating, especially when it comes to COVID-19 vaccinations. But prioritizing who receives the limited supply of vaccines available saves lives and reduces spread of infection, according to a study published in the journal PNAS from the University of California, Davis.

Undetected coronavirus variant was in at least 15 countries before its discovery

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The University of Texas at Austin COVID-19 Modeling Consortium. Scientists first discovered it in early December in the United Kingdom, where the highly contagious and more lethal variant is thought to have originated.

COVID-19 survivors might need just one dose of two-part vaccine

A single dose of the Pfizer-BioNTech vaccine for individuals who previously had COVID-19 generates an immunologic response similar to that of individuals receiving the two-dose recommended sequence, according to a Cedars-Sinai study published today by the journal Nature Medicine.

B.1.1.7 variant of COVID-19 spreading rapidly in United States

The faster-spreading B.1.1.7 variant of SARS-CoV-2 first detected in the United Kingdom, the coronavirus that causes COVID-19, is quickly on its way to becoming the dominant variant of the virus in the United States, according to a study from scientists at Scripps Research and the COVID-19 test maker Helix.

Research & Development News

Clinical trial completion rates decline during COVID-19 pandemic

Study identifies possible COVID-19 drugs - including several that are FDA-approved

COVID-19 convalescent plasma with greater antibody levels is safe and shows promise

Prioritizing who gets vaccinated for COVID-19 saves lives

Undetected coronavirus variant was in at least 15 countries before its discovery

COVID-19 survivors might need just one dose of two-part vaccine

B.1.1.7 variant of COVID-19 spreading rapidly in United States

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs